WithdrawnPhase 1NCT07123363

Effect of Bitopertin on the Liver and on Levels of Protoporphyrin IX in Bile, Blood, Liver, and Stool in Patients With Erythropoietic Protoporphyria/X-linked Protoporphyria and Increased Liver Stiffness and/or Liver Enzymes at Baseline

Studying Autosomal erythropoietic protoporphyria

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Wake Forest University Health Sciences
Principal Investigator: Herbert Bonkovsky, MD
Atrium Health Wake Forest Baptist
Intervention: bitopertin(drug)
Eligibility: 18-75 years · All sexes
Timeline: 2026 – 2035

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07123363 on ClinicalTrials.gov

Other trials for Autosomal erythropoietic protoporphyria

Additional recruiting or active studies for the same condition.

ENROLLING BY INVITATIONPHASE2, PHASE3NCT05883748
HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
Disc Medicine, Inc

See all trials for Autosomal erythropoietic protoporphyria →

← Back to all trials